The use of PTC and RFA as treatment alternatives with low procedural morbidity in non-small cell lung cancer.

Choe, Yeong Hun; Kim, So Ri; Lee, Kyung Sun; Lee, Ka Young; Park, Seoung Ju; Jin, Gong Yong; Lee, Yong Chul
European journal of cancer (Oxford, England : 1990)
2009Jul ; 45 ( 10 ) :1773-9.
ÀúÀÚ »ó¼¼Á¤º¸
Choe, Yeong Hun -
Kim, So Ri -
Lee, Kyung Sun -
Lee, Ka Young -
Park, Seoung Ju -
Jin, Gong Yong -
Lee, Yong Chul -
ABSTRACT
Minimally invasive percutaneous ablative therapies for treating lung cancers are currently being studied as treatment alternatives. This present study investigated the efficacies of percutaneous thoracic cryotherapy (PTC) and radiofrequency ablation (RFA) on clinical courses of pulmonary malignant tumours, especially in the setting of non-surgical candidates. Sixty-five patients with lung malignancy underwent sixty-seven sessions of RFA and nine sessions of PTC. We evaluated the results of RFA and PTC including efficacies, local progression rate, survival rate, and complications. Twenty-nine patients (43.3%) treated with RFA and six patients (66.7%) with PTC attained complete ablation. In small-sized lung mass (3 cm), complete ablation rate of RFA and PTC was increased to 76.2% and 85.7%, respectively. Additionally, we have found that the complete ablation group had significantly higher survival duration and progression free survival duration compared with the partial ablation group. Moreover, the complication profile was acceptable and the pain associated with the procedures disappeared within 1 day; 42 patients (62.7%) after RFA and all patients after PTC. This study provides evidence for the use of PTC and RFA as treatment alternatives with low procedural morbidity in the management of inoperable pulmonary malignant tumours, although the current study is limited by the small sample size and the short follow-up period.
Lung malignancy Morbidity Mortality Percutaneous cryotherapy Radiofrequency ablation
MESH
Aged, Carcinoma, Non-Small-Cell Lung/pathology/radiography/*surgery, Catheter Ablation/adverse effects/*methods, Cryosurgery/adverse effects/*methods, Disease Progression, Female, Humans, Lung Neoplasms/pathology/radiography/*surgery, Male, Middle Aged, Minimally Invasive Surgical Procedures/methods, Neoplasm Staging, Pain, Postoperative/etiology, Survival Analysis, Tomography, X-Ray Computed, Treatment Outcome
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Lung malignancy Morbidity Mortality Percutaneous cryotherapy Radiofrequency ablation RFA and PTC are promising treatment modalities for pulmonary malignant tumours with satisfactory outcome of tumour destruction, especially for tumours less than or equal to 3.0 cm in diameter.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
10.1016/j.ejca.2009.02.016
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå